BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (July 2016)

28 slides from BioSpecifics Technologies's investor presentation, Jul 1, 2016

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE C —_ Cpr BioSpecifics July 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: B. 6 @ Originator ! Profitable : Receives ! Future ! BioSpecifics of collagenase | biopharma : revenues ' revenue growth developing based-therapies | companywith | fromXlAFLEX® opportunities 1 XIAFLEX for lean corporate ; milestones, from robust ; medically structure and :

  4. Slide 4: Unlocking Vast Potential of XIAFLEX

    Unlocking Vast Potential of XIAFLEX® XIAFLEX: First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications Drive R&D in new indications to early proof-of-con

  5. Slide 5: Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options

    Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options

  6. Slide 6: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: Source: Endo Internati

  7. Slide 7: Commercial Highlights for Dupuytren's Contracture

    Commercial Highlights for Dupuytren’ Contracture ~6,634 demand vials in 1Q16 ~1.2 vials/patient Statistically significant results from Phase 2a study in Dupuytren’s nodules Nodules are far more prevalent than contractures Endo to begin registration trial in 4Q16* Updated U.S. label including recurre

  8. Slide 8: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  9. Slide 9: Commercial Highlights for Peyronie's Disease

    Commercial Highlights for Peyronie’s Disease ~7,378 demand vials in 1Q16 ~4.5 vials/patient In May 2015: The American Urological Association presented first ever treatment guidelines for PD, recommending the use of XIAFLEX® in combination with modeling in patients with stable disease Positive data s

  10. Slide 10: XIAFLEX 1Q16 Sales and Future Growth Initiatives

    XIAFLEX 1Q16 Sales and Future Growth Initiatives 1Q16 U.S. net sales were $44.0 million, a 57% increase vs. 1Q15 FUTURE GROWTH INITIATIVES: Broaden physician base with improved targeting to reach the most appropriate physicians Direct to consumer campaign traction Dupuytren’s contracture print ads P

  11. Slide 11: Pipeline Indications

    XIAFLEX® Pipeline Indications

  12. Slide 12: Pipeline Programs

    XIAFLEX® Pipeline Programs Future Revenue-Generating Opportunities Phase 2b initiated in Cellulite endo aS 1016 pate RE bles atk a endo 5 Capsulitis 3Q16' Statistically significant Human Phase 2 top-line Lipoma results reported in June 2016 ; Endo has license (ona ¢ ae Pp development Uterine a SAG F

  13. Slide 13: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera

  14. Slide 14: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis/Frozen Shoulder Syndrome

    Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results 321 patient double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Primary endpoint: change in degrees from baseline to Da

  15. Slide 15: Cellulite

    XIAFLEX® for Cellulite Phase 2b Study Initiated in February 2016 Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Phase 2b Study Design Enrolling 350 women (18+ years) Up to 3 treatment sessions

  16. Slide 16: Cellulite

    XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line data from Phase 2a study: 150 women received up to three treatment sessions of drug or placebo according to randomization (5 high-dose (0.84mg): 5 mid (0.48mg): 5 low (0.06mg): 3 placebo) Mid and high level XIAFLEX® doses dem

  17. Slide 17: Human Lipomas

    XIAFLEX® for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Definition Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapi

  18. Slide 18: Positive Top-Line Phase Study Results

    Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of CCH Primary endpoint: 81.3% reduction in visible surface area for CCH vs. 2.1% increase for placebo; 83.4% difference in favor of CCH (p<0.0001) 89.5% responder rate (showed a 250% decrease in lipoma visible surface area relative to

  19. Slide 19: Lipomas in Canines

    XIAFLEX® for Lipomas in Canines Potential to be Only FDA Approved Nonsurgical Therapy Key Complications Market Opportunity Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affec

  20. Slide 20: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Clinical Trial to Begin in 2H16 Definition & Key Complications U.S. Market Opportunity Encouraging Preclinical Data Benign tumors in the reproductive tract that contain large amounts of collagen Cause pelvic discomfort and pain, decreased fertility, pregnancy complicati

  21. Slide 21: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Phase 2 Trial to Begin in 4Q16* Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise an

  22. Slide 22: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Phase 2 Trial to Begin in 3Q16* Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease

  23. Slide 23: Additional Promising Unlicensed Indications

    Additional Promising Unlicensed Indications Capsular Contracture, Breast: Post-surgical complication that can deform the breast and cause pain ~15% of breast augmentation / reconstructive surgery patients Hypertrophic Scars & Keloids: Scars that form on the skin at site of injury ~600,000 scar and ~

  24. Slide 24: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$89.3M Received as of March 31, 2016 Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Sublicense Income from Endo Partnerships $89.3M received in licensing, sublicensing, milestone, COGS, and royalty payments as of M

  25. Slide 25: Strong IP Portfolio

    Strong IP Portfolio Long-term patent protection for CCH Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owned, co

  26. Slide 26: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the quarter ended 03/31/16 03/31/15 Cash and equivalents, and investments $44,263,035 $24,994,544 Income Statement Revenues 6,567,991 $5,606,454 Other income 74,061 18,353 Costs and expenses (2,412,833) (2,042,587) Provision for i

  27. Slide 27: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones Human Lipomas* Uterine Fibroids* Adhesive Capsulitis Cellulite Lateral Hip Fat Plantar Fibromatosis Dupuytren’s nodules lil] Oo * BioSpecifics-managed development programs **Based on mast recent public statements made by Endo International ple Potential for E

  28. Slide 28: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of INJECTABLE COLLAGENASE te ep. BioSpecifics July 2016

Biospecifics Technologies — Investor Presentation (July 2016) on 6ix